[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614386":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":38,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Mosunetuzumab","Adult patients (\\>18 years) with Follicular Non-Hodgkin Lymphoma, who have undergone at least two lines of therapy, treated with Mosunetuzumab under a compassionate use program",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Andres JM Ferreri, Prof","CONTACT","0226439396","ferreri.clinicaltrials@hsr.it",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"IRCCS Ospedale San Raffaele","RECRUITING","Milan","20132","Italy","IT",{"type":28,"coordinates":29},"Point",[30,31],12.59836,42.78235,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":36,"phoneExt":7,"email":37},"Prof. Andrés JM Ferreri","02-2643- 9396","urc.ul@hsr.it",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Andrés José Maria Ferreri","Prof.","100614386","study-to-evaluate-the-response-to-treatment-with-mosunetuzumab-in-relapsedrefractory-follicular-lymphoma-fl-after-at-least-two-lines-of-therapy-within-the-compassionate-use-program-cup-100614386",false,"NCT07278921","Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed\u002FRefractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).","Retrospective, Multicenter Observational Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed\u002FRefractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).","MosuOSSHSR","Inclusion Criteria:\n\n* Adult patients (\\>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two lines of therapy, treated with mosunetuzumab under a compassionate use program.\n* Patients who have signed informed consent for treatment.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Patients with other types of cancer\u002Flymphoma\n* Patients not eligible for the Mosunetuzumab compassionate use program","ALL","18 Years",{"count":53,"type":54},25,"ESTIMATED","OBSERVATIONAL","Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed\u002Frefractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).",[58],"Relapsed\u002FRefractory Follicular Lymphoma","2026-01-30",{"date":61,"type":62},"2026-02-03","ACTUAL",{"date":64,"type":62},"2025-12-01",{"date":66,"type":54},"2026-12-31",{"name":40,"class":6},1]